ClinicalTrials.gg
CompletedNCT02460497Updated Aug 1, 2023Results posted

Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia

An interventional study of Treatment: Minoxidil 2% / Botanical Hair Solution for Women in Female Pattern Hair Loss, Androgenic Alopecia, sponsored by Galderma R&D. Completed at 1 site in United States. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Galderma R&D (part of Galderma Group AG) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.

Enrollment
15th of 31
61 · median 60
Started
2015
with 2 others
No phase
8 of 31
3 open now
Registered
7th of 31
by date
Lead sponsor
2 of 31
Galderma R&D

Among the 31 studies testing minoxidil in Alopecia, this one is the 15th largest by enrollment, is one of 3 that started in 2015, is one of 8 with no phase, and was the 7th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About minoxidil

Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 74 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 46 (62%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing minoxidil in Alopecia, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the effect of Minoxidil 2% Solution and Botanical Hair Solution Regimen in women with thinning hair and female pattern hair loss/androgenic alopecia (Ludwig I and II).

03

Conditions studied

  • Female Pattern Hair Loss, Androgenic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Female patients age 18 to 60 years at the time of enrollment.
  2. Women who have self-perceived thinning hair.
  3. Women who have presentation of female pattern hair loss/androgenic alopecia (Ludwig I and II).

Key Exclusion Criteria:

  1. History of allergic reactions or severe intolerance to minoxidil and Botanical Hair Solution product ingredients.
  2. Plan to use any other concomitant therapy to treat hair loss, regrowth or volume during the study.

3 Subjects taking or planning to take topical or systemic prescription or OTC medications for treating hair loss and/or hair volume.

  1. Any significant history of concurrent medical disease, which in the judgment of the Investigator, would make the subject inappropriate for entry to this study including history of skin disease that may confound study results.
  1. Subjects who have recently (within the last 6 months) started the use of hormones for or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study.
  1. Pregnant or breast-feeding females or women planning to become pregnant during the course of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Treatment

    Drug: Treatment: Minoxidil 2% / Botanical Hair Solution for Women

Interventions

  • DrugTreatment: Minoxidil 2% / Botanical Hair Solution for Women

    Drug page: Minoxidil

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Investigator's Rating of Global Photographs at Week 12

    The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale. The score on the scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.

    Time frame: At Week 12

Secondary outcomes

  1. Change From Baseline in Participant Rating at Week 12

    Participants rated the parameters like appearance of hair, growth of hair, satisfaction with Hairline at the front of the head, satisfaction with hair on the top of the head and satisfaction with hair overall as an overall improvement from the baseline by conducting their own assessments by looking in a mirror and evaluating improvement from baseline using a 1 to 7-point Likert scale. The scores on the scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.

    Time frame: At Week 12

  2. Mean Change From Baseline in Shed Hair Count

    Participants collected their hair full day, including after combing and hair-washing. Participants turned in these hair collections at each visit. The results were averaged weekly. Mean change from baseline in hair wash/shed hair count was reported at week 12.

    Time frame: At Week 12

  3. Number of Participants in Each Response Category Based on Subject Satisfaction Questionnaire

    Participant satisfaction with the treatment experience data was collected via a written questionnaire This questionnaire composed of 5-point Likert scale questions, as well as free-text responses. Participants were asked to determine overall satisfaction with the treatment. The choices were: 1-2 = Agree; 4-5 = Disagree; 3 = Neutral.

    Time frame: At Week 4, 6 and 12

  4. Number of Participants With Adverse Events (AEs)

    AEs were defined as any untoward medical occurrence associated with the use of a study product in humans, whether or not considered study product related. An AE could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study product and would not imply any judgment about causality. An AE could arise with any use of the study product and with any route of administration, formulation, or dose, including an overdose. Thus any new sign, symptom or disease, or clinically significant increase in the intensity of an existing sign, or symptom would be considered as an AE. Any new clinically relevant sign or symptom suffered by the participant, which appeared after the study procedures was reported as an AE. Any worsening in scalp dryness or itch score from baseline was also reported as an AE. The Investigator or designee had the final authorization to determine if a reaction was considered an AE.

    Time frame: From start of study drug administration up to Week 12

07

Results

Posted Aug 1, 2023

Participant flow

The study was conducted at 1 center in the United States from 27 May 2015 to 19 September 2015.

Participant flow — Overall Study
MilestoneMinoxidil 5% Foam and Botanical Hair Solution
Started61
Intent-to-treat (itt) population54
Safety population (sp)60
Completed52
Not completed9
Withdrew: Participant requested withdrawal4
Withdrew: Non-compliance1
Withdrew: Did not meet protocol criteria1
Withdrew: Lost to follow-up2
Withdrew: Investigator decision1

Outcome measures

PrimaryChange From Baseline in Investigator's Rating of Global Photographs at Week 12

The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale. The score on the scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.

Time frame:
At Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in Investigator's Rating of Global Photographs at Week 12
Score on a scaleMinoxidil 5% Foam and Botanical Hair Solution
Hair Thinning4.9 ± 0.9
Hair Growth4.9 ± 0.8
Impression of scalp hair coverage4.8 ± 0.8
Overall perception of treatment benefit5.0 ± 0.9
SecondaryChange From Baseline in Participant Rating at Week 12

Participants rated the parameters like appearance of hair, growth of hair, satisfaction with Hairline at the front of the head, satisfaction with hair on the top of the head and satisfaction with hair overall as an overall improvement from the baseline by conducting their own assessments by looking in a mirror and evaluating improvement from baseline using a 1 to 7-point Likert scale. The scores on the scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.

Time frame:
At Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in Participant Rating at Week 12
Score on a scaleMinoxidil 5% Foam and Botanical Hair Solution
Appearance of hair5.6 ± 1.3
Growth of hair5.4 ± 1.5
Satisfaction with hairline at the front of the head5.1 ± 1.5
Satisfaction with hair on the top of the head5.1 ± 1.5
Satisfaction with hair overall as an overall improvement from the baseline5.5 ± 1.5
SecondaryMean Change From Baseline in Shed Hair Count

Participants collected their hair full day, including after combing and hair-washing. Participants turned in these hair collections at each visit. The results were averaged weekly. Mean change from baseline in hair wash/shed hair count was reported at week 12.

Time frame:
At Week 12
Reported as:
Mean · Shed Hair Count
Mean Change From Baseline in Shed Hair Count
Shed Hair CountMinoxidil 5% Foam and Botanical Hair Solution
Mean Change From Baseline in Shed Hair Count4.9 ± 121.8
SecondaryNumber of Participants in Each Response Category Based on Subject Satisfaction Questionnaire

Participant satisfaction with the treatment experience data was collected via a written questionnaire This questionnaire composed of 5-point Likert scale questions, as well as free-text responses. Participants were asked to determine overall satisfaction with the treatment. The choices were: 1-2 = Agree; 4-5 = Disagree; 3 = Neutral.

Time frame:
At Week 4, 6 and 12
Reported as:
Count of participants · Participants
Number of Participants in Each Response Category Based on Subject Satisfaction Questionnaire
ParticipantsMinoxidil 5% Foam and Botanical Hair Solution
I have noticed an improvement in the appearance of my hair (At Week 4) — Agree27
I have noticed an improvement in the appearance of my hair (At Week 4) — Disagree13
I have noticed an improvement in the appearance of my hair (At Week 4) — Neutral14
I have noticed an improvement in the appearance of my hair (At Week 6) — Agree37
I have noticed an improvement in the appearance of my hair (At Week 6) — Disagree9
I have noticed an improvement in the appearance of my hair (At Week 6) — Neutral8
I have noticed an improvement in the appearance of my hair (At Week 12) — Agree45
I have noticed an improvement in the appearance of my hair (At Week 12) — Disagree4
I have noticed an improvement in the appearance of my hair (At Week 12) — Neutral5
This Regimen provides thicker looking hair (At Week 4) — Agree25
This Regimen provides thicker looking hair (At Week 4) — Disagree15
This Regimen provides thicker looking hair (At Week 4) — Neutral14
This Regimen provides thicker looking hair (At Week 6) — Agree38
This Regimen provides thicker looking hair (At Week 6) — Disagree10
This Regimen provides thicker looking hair (At Week 6) — Neutral6
My hair looks fuller (At Week 4) — Agree25
My hair looks fuller (At Week 4) — Disagree16
My hair looks fuller (At Week 4) — Neutral13
My hair looks fuller (At Week 6) — Agree35
My hair looks fuller (At Week 6) — Disagree9
My hair looks fuller (At Week 6) — Neutral10
My hair looks noticeably fuller (At Week 12) — Agree38
My hair looks noticeably fuller (At Week 12) — Disagree8
My hair looks noticeably fuller (At Week 12) — Neutral6
This Regimen provides healthier looking hair (At Week 4) — Agree26
This Regimen provides healthier looking hair (At Week 4) — Disagree12
This Regimen provides healthier looking hair (At Week 4) — Neutral16
This Regimen provides healthier looking hair (At Week 6) — Agree31
This Regimen provides healthier looking hair (At Week 6) — Disagree8
This Regimen provides healthier looking hair (At Week 6) — Neutral15
I am happy with the appearance of hair (At Week 4) — Agree24
I am happy with the appearance of hair (At Week 4) — Disagree17
I am happy with the appearance of hair (At Week 4) — Neutral13
I am happy with the appearance of hair (At Week 6) — Agree31
I am happy with the appearance of hair (At Week 6) — Disagree12
I am happy with the appearance of hair (At Week 6) — Neutral11
This Regimen improves my hair volume (At Week 4) — Agree24
This Regimen improves my hair volume (At Week 4) — Disagree18
This Regimen improves my hair volume (At Week 4) — Neutral12
This Regimen improves my hair volume (At Week 6) — Agree35
This Regimen improves my hair volume (At Week 6) — Disagree8
This Regimen improves my hair volume (At Week 6) — Neutral11
This Regimen improves my hair volume (At Week 12) — Agree43
This Regimen improves my hair volume (At Week 12) — Disagree5
This Regimen improves my hair volume (At Week 12) — Neutral6
This Regimen improves my hair texture (At Week 4) — Agree22
This Regimen improves my hair texture (At Week 4) — Disagree17
This Regimen improves my hair texture (At Week 4) — Neutral15
This Regimen improves my hair texture (At Week 6) — Agree28
This Regimen improves my hair texture (At Week 6) — Disagree10
This Regimen improves my hair texture (At Week 6) — Neutral16
This Regimen improves my hair texture (At Week 12) — Agree36
This Regimen improves my hair texture (At Week 12) — Disagree10
This Regimen improves my hair texture (At Week 12) — Neutral8
I have noticed an improvement in my hair quality (At Week 4) — Agree26
I have noticed an improvement in my hair quality (At Week 4) — Disagree12
I have noticed an improvement in my hair quality (At Week 4) — Neutral16
I have noticed an improvement in my hair quality (At Week 6) — Agree35
I have noticed an improvement in my hair quality (At Week 6) — Disagree6
I have noticed an improvement in my hair quality (At Week 6) — Neutral13
I have noticed an improvement in my hair quality (At Week 12) — Agree41
I have noticed an improvement in my hair quality (At Week 12) — Disagree7
I have noticed an improvement in my hair quality (At Week 12) — Neutral6
My scalp feels better since beginning this Regimen (At Week 4) — Agree24
My scalp feels better since beginning this Regimen (At Week 4) — Disagree13
My scalp feels better since beginning this Regimen (At Week 4) — Neutral17
My scalp feels better since beginning this Regimen (At Week 6) — Agree27
My scalp feels better since beginning this Regimen (At Week 6) — Disagree6
My scalp feels better since beginning this Regimen (At Week 6) — Neutral21
My hair looks stronger (At Week 4) — Agree29
My hair looks stronger (At Week 4) — Disagree10
My hair looks stronger (At Week 4) — Neutral15
My hair looks stronger (At Week 6) — Agree35
My hair looks stronger (At Week 6) — Disagree8
My hair looks stronger (At Week 6) — Neutral11
My hair looks stronger (At Week 12) — Agree43
My hair looks stronger (At Week 12) — Disagree6
My hair looks stronger (At Week 12) — Neutral5
I like the Regimen I used in this study (At Week 12) — Agree43
I like the Regimen I used in this study (At Week 12) — Disagree5
I like the Regimen I used in this study (At Week 12) — Neutral4
I received compliments from friends and family members about my hair (At Week 12) — Agree23
I received compliments from friends and family members about my hair (At Week 12) — Disagree16
I received compliments from friends and family members about my hair (At Week 12) — Neutral13
I would recommend this Regimen to others (At Week 12) — Agree42
I would recommend this Regimen to others (At Week 12) — Disagree6
I would recommend this Regimen to others (At Week 12) — Neutral4
I feel younger (At Week 12) — Agree23
I feel younger (At Week 12) — Disagree10
I feel younger (At Week 12) — Neutral19
I thought this Regimen did better than my previous hair thinning products (At Week 12) — Agree23
I thought this Regimen did better than my previous hair thinning products (At Week 12) — Disagree8
I thought this Regimen did better than my previous hair thinning products (At Week 12) — Neutral21
I feel more attractive (At Week 12) — Agree33
I feel more attractive (At Week 12) — Disagree11
I feel more attractive (At Week 12) — Neutral8
I feel more sociable (At Week 12) — Agree26
I feel more sociable (At Week 12) — Disagree11
I feel more sociable (At Week 12) — Neutral15
I feel more confident (At Week 12) — Agree31
I feel more confident (At Week 12) — Disagree9
I feel more confident (At Week 12) — Neutral12
I would purchase this Regimen (At Week 12) — Agree40
I would purchase this Regimen (At Week 12) — Disagree6
I would purchase this Regimen (At Week 12) — Neutral6
My hair looks heathier (At Week 12) — Agree43
My hair looks heathier (At Week 12) — Disagree5
My hair looks heathier (At Week 12) — Neutral4
SecondaryNumber of Participants With Adverse Events (AEs)

AEs were defined as any untoward medical occurrence associated with the use of a study product in humans, whether or not considered study product related. An AE could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study product and would not imply any judgment about causality. An AE could arise with any use of the study product and with any route of administration, formulation, or dose, including an overdose. Thus any new sign, symptom or disease, or clinically significant increase in the intensity of an existing sign, or symptom would be considered as an AE. Any new clinically relevant sign or symptom suffered by the participant, which appeared after the study procedures was reported as an AE. Any worsening in scalp dryness or itch score from baseline was also reported as an AE. The Investigator or designee had the final authorization to determine if a reaction was considered an AE.

Time frame:
From start of study drug administration up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsMinoxidil 5% Foam and Botanical Hair Solution
Number of Participants With Adverse Events (AEs)2

Adverse events

Collected over From start of study drug administration up to Week 12. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Minoxidil 5% Foam and Botanical Hair Solution0/60 (0%)0/60 (0%)4/60 (6.7%)
Most frequent other events
Most frequent other events
EventMinoxidil 5% Foam and Botanical Hair Solution
Back PainMusculoskeletal and connective tissue disorders1/60
Abdominal painGastrointestinal disorders1/60
NauseaGastrointestinal disorders1/60
InfluenzaGastrointestinal disorders1/60

Baseline characteristics

SP included all participants who were enrolled and received at least one dose of study product.

Age, Continuous
Age, Continuous(years)Minoxidil 5% Foam and Botanical Hair Solution
Mean46.9 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Minoxidil 5% Foam and Botanical Hair Solution
Female60
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Minoxidil 5% Foam and Botanical Hair Solution
Race — Asian5
Race — Black or African American12
Race — Hispanic or Latino11
Race — White31
Race — Multi-Racial1
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)Minoxidil 5% Foam and Botanical Hair Solution
II15
III17
IV21
V7
08

Study locations

1 site
  • Stephens & Associates
    Richardson, Texas 75081, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Sep 2015, 3 months.

Results were first posted in Aug 2023, 7 years 10 months after primary completion.

Of 61 industry-sponsored interventional studies with no phase under Alopecia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 3 months is below that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2015
First posted
Jun 2, 2015
StartActual
May 27, 2015
Primary completionActual
Sep 19, 2015
CompletionActual
Sep 19, 2015
Results first posted
Aug 1, 2023
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02460497
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 2, 2015
Start date
May 27, 2015
Primary completion
Sep 19, 2015
Completion
Sep 19, 2015
Results posted
Aug 1, 2023
Last update
Aug 1, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minoxidil

Start the discussion